Breast Cancer
Conference Coverage
ASCO: Omitting adjuvant radiation after pCR ups locoregional recurrence risk
Key clinical point: Adjuvant radiation therapy improves locoregional recurrence–free survival after neoadjuvant chemo and surgery for breast...
News
Advanced breast cancer: paclitaxel bests nab-paclitaxel, ixabepilone
Key clinical point: Newly developed agents nab-paclitaxel and ixabepilone both failed to outperform paclitaxel against advanced breast cancer....
Conference Coverage
VIDEO: Dr. William J. Gradishar provides take-home messages from ASCO 2015
Expert gives his take on bevacizumab, T-DM1, palbociclib, and neratinib.
Conference Coverage
Three bisphosphonates found on par in early breast cancer
Key clinical point: Adjuvant zoledronic acid, clodronate, and ibandronate yield similar disease-free survival in early breast cancer. Major...
Conference Coverage
ASCO: Precision medicine initiatives take wing
News
ASCO: Adjuvant neratinib has payoff in HER2-positive breast cancer
Key clinical point: Neratinib reduces the risk of recurrence of invasive disease in women with early HER2-positive breast cancer. Major finding:...
Conference Coverage
Anastrozole provides alternative option for DCIS
Key clinical point: Anastrozole is an alternative option for adjuvant treatment of postmenopausal DCIS. Major finding: Breast cancer–free rates at...
News
ASCO: Enzalutamide advances in triple-negative breast cancer
Key clinical point: Enzalutamide is active in androgen receptor–positive triple-negative breast cancer. Major finding: The 16-week clinical...
News
CDK inhibitor remains active as endocrine resistance emerges
Key clinical point: Palbociclib given with hormonal therapy is efficacious in women with hormone receptor–positive metastatic breast cancer...